Skip to main content
SpringerLink
Log in
Book cover

Immunoproteomics pp 361–367Cite as

Commercial Considerations for Immunoproteomics

  • Protocol
  • First Online:

  • 2838 Accesses

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1061))

Abstract

The underlying drivers of scientific processes have been rapidly evolving, but the ever-present need for research funding is typically foremost amongst these. Successful laboratories are embracing this reality by making certain that their projects have commercial value right from the beginning of the project conception. Which factors to be considered for commercial success need to be well thought out and incorporated into a project plan with similar levels of detail as would be the technical elements. Specific examples of commercial outcomes in the field of Immunoproteomics are exemplified in this discussion.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Covey SR (1989) The 7 habits of highly effective people. Simon & Schuster, New York

    Google Scholar 

  2. Kassicieh SK, Radosevich HR (1994) From lab to market: commercialization of public sector technology. Plenum, New York

    Book  Google Scholar 

  3. Sarna L (2000) Guide to commercializing R&D. Jewel Publications Ltd., Montreal, QC

    Google Scholar 

  4. Jolly VK (1997) Commercializing new technologies: getting from mind to market. Harvard Business School Press, Boston, MA

    Google Scholar 

  5. Kaplam RS, Norton DP (2004) Strategy maps: converting intangible assets into tangible outcomes. Harvard Business School Publishing Corporation, Boston, MA

    Google Scholar 

  6. Tidd J, Bessant J, Pavitt K (2001) Managing innovation: integrating technological, market and organizational change. Wiley, Chichester

    Google Scholar 

  7. Lane RP, Daly PB (2006) Managing biotechnology risk from concept to commercialization: a strategic approach. BioExecutive International April 2006

    Google Scholar 

  8. Branca MA (2004) The path to market for genomics-based diagnostics. Spectrum diagnostics and related technologies. Decision Resources, Waltham, MA

    Google Scholar 

  9. Krul KG (1999) Pharmagogenomics: key technologies, major players, and lingering questions. Spectrum pharmaceutical industry dynamics. Decision Resources, Waltham, MA

    Google Scholar 

  10. Miller T (2000) Challenges in genomics-based biotechnology: Part I: building a proprietary technology portfolio. Spectrum pharmaceutical industry dynamics. Decision Resources, Waltham, MA

    Google Scholar 

  11. Miller T (2000) Challenges in genomics-based biotechnology: Part II: key genomics leaders. Spectrum pharmaceutical industry dynamics. Decision Resources, Waltham, MA

    Google Scholar 

  12. Haberman A (2001) Protein biochips: an emerging technology for proteomics. Spectrum drug discovery and design. Decision Resources, Waltham, MA

    Google Scholar 

  13. Lockwood D, Branca M (2001) Genomics dealmaking in 2000 and future outlook, Part II: proteomics and functional genomics. Spectrum drug discovery and design. Decision Resources, Waltham, MA

    Google Scholar 

  14. Krul KG (2001) Advances in proteomics: its use and commercialization. Spectrum pharmaceutical industry dynamics. Decision Resources, Waltham, MA

    Google Scholar 

  15. Matheson A (1998) Profiting from proteomics: strategies and technologies. Scrip Reports, BS 982, UK

    Google Scholar 

  16. Crowther G (2012) Biomarker discovery methods evolving. Genet Eng Biotechnol News 32(9):44

    Article  Google Scholar 

  17. Mou Z, He Y, Wu Y (2009) Immunoproteomics to identify tumor-associated antigens eliciting humoral response. Cancer Lett 278:123–129

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Human Health Therapeutics Portfolio, National Research Council Canada, Ottawa, ON, Canada

    Scott M. Ferguson

Authors
  1. Scott M. Ferguson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Research Council Canada Human Health Therapeutics, Ottawa, Ontario, Canada

    Kelly M. Fulton

  2. National Research Council Canada Human Health Therapeutics, Ottawa, Ontario, Canada

    Susan M. Twine

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Ferguson, S.M. (2013). Commercial Considerations for Immunoproteomics. In: Fulton, K., Twine, S. (eds) Immunoproteomics. Methods in Molecular Biology, vol 1061. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-589-7_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-589-7_22

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-588-0

  • Online ISBN: 978-1-62703-589-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation